Enfuvirtide (Fuzeon)

A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.

Also Known As:

Networked: 194 relevant articles (10 outcomes, 17 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	He, Yuxian: 11 articles (01/2020 - 10/2008)
2.	Chong, Huihui: 9 articles (01/2020 - 07/2009)
3.	Jiang, Shibo: 8 articles (08/2015 - 01/2004)
4.	Zhu, Yuanmei: 7 articles (01/2020 - 01/2017)
5.	Salgo, Miklos: 7 articles (11/2008 - 05/2003)
6.	Reynes, Jacques: 5 articles (09/2011 - 07/2002)
7.	Moral, M A: 5 articles (12/2010 - 05/2009)
8.	Tomillero, A: 5 articles (12/2010 - 05/2009)
9.	Raffi, François: 5 articles (10/2009 - 05/2004)
10.	Lu, Lu: 4 articles (08/2015 - 02/2011)

Related Diseases

1.	HIV Infections (HIV Infection) 10/01/2003 - "Enfuvirtide, a new treatment for HIV infection." 02/01/2007 - "To optimize enfuvirtide use, consensus recommendations for this purpose have been formulated by 247 physicians attending patients with HIV infection in Spain. " 02/01/2007 - "Enfuvirtide is a high-cost, parenterally administered drug commonly used in late phases of HIV infection, when its efficacy may be compromised. " 07/01/2005 - "Enfuvirtide, the first fusion inhibitor to treat HIV infection." 04/25/2005 - "Whereas the only previously approved medication from this group, enfuvirtide, can be only injected subcutaneously and, thus, is indicated for only treatment-experienced patients, the CCR5 antagonists represent a group of experimental medications whose use is conceivable at all stages of the HIV infection. "
2.	Infections 11/01/2013 - "ccN28Fd was effective in inhibiting infection by a broad spectrum of primary HIV-1 isolates and enfuvirtide-resistant strains and blocking cell-to-cell HIV-1 transmission. " 08/24/2022 - "It is capable of delivering enfuvirtide with effective concentrations to prevent women from HIV-1 infection." 11/15/2019 - "GPI-anchored 2P23 (GPI-2P23) completely protected TZM-bl cells from infections of divergent HIV-1, HIV-2, and SIV isolates as well as a panel of enfuvirtide (T20)-resistant mutants. " 06/01/2014 - "Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. " 10/01/2012 - "Enfuvirtide belongs to a newer class of antiretroviral (ARV) agents called fusion inhibitors for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. "
3.	Injection Site Reaction 01/01/2010 - "The fusion inhibitor enfuvirtide has demonstrated efficacy in heavily treatment-experienced patients, although injection-site reactions can be problematical. " 07/01/2008 - "The aim of this study was to evaluate the quality of life and the intensity of the injection site reactions during the first 6 months of treatment with enfuvirtide according to the counseling and training provided by nurses and physicians. " 01/01/2008 - "A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)." 01/01/2008 - "This study correlated the clinical and histopathological pattern of injection-site reactions (ISRs) to the pharmacokinetics of enfuvirtide in patients with HIV. " 10/01/2012 - "Enfuvirtide and cutaneous injection-site reactions."
4.	Viremia 07/01/2009 - "In this study, we have investigated whether the fusion-inhibitor enfuvirtide (ENF) can induce mutations in Rev and if these mutations correlate with the classical ENF resistance gp41 mutations and with viremia and CD4 cell count. " 08/01/2008 - "Breakthrough HIV viremia was associated with worsening symptoms in two patients at 5 and 18 months of enfuvirtide use. " 06/01/2008 - "Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations." 12/01/2009 - "A switch to raltegravir in virologically suppressed patients on enfuvirtide is effective in maintaining immunologic and virologic control at 24 weeks but did not result in a change in residual viremia." 12/01/2009 - "To characterize safety and efficacy of an enfuvirtide to raltegravir switch including changes in T-cells, quality of life, and residual viremia. "
5.	Inflammation (Inflammations) 02/01/2011 - "This study shows that suppression of HIV-1 replication with enfuvirtide-based salvage therapy in patients with low CD4 cell counts may result in an immunological benefit, characterized by the restoration of CD4 T-cell subsets associated with decreased immune activation and suppression of inflammation." 01/01/2017 - "In ART switch studies, changing to an integrase inhibitor from a PI-, NNRTI-, or enfuvirtide-containing regimen has resulted in improvement in several markers of inflammation. "

Related Drugs and Biologics

1.	Raltegravir Potassium
2.	Peptides (Polypeptides)
3.	Integrase Inhibitors
4.	Antiviral Agents (Antivirals)
5.	Anti-Retroviral Agents (Antiretroviral Agents)
6.	RNA (Ribonucleic Acid)
7.	Integrases
8.	Melitten (Melittin)
9.	Lactoferrin
10.	rupintrivir

Related Therapies and Procedures

1.	Therapeutics
2.	Salvage Therapy
3.	Aftercare (After-Treatment)
4.	Highly Active Antiretroviral Therapy (HAART)
5.	Injections